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Abstract
Background: The most important goal for survival benefit of advanced stage ovarian cancer is to surgically remove
all visible tumour, because complete cytoreductive surgery (CCS) has been shown to be associated with prolonged
survival.
In a remarkable number of women, CCS is very challenging. Especially in women with many small metastases on
the peritoneum and intestinal surface, conventional CCS with electrosurgery is not able to be “complete” in
removing safely all visible tumour.
In this randomized controlled trail (RCT) we investigate whether the use of the PlasmaJet Surgical Device increases
the rate of CCS, and whether this indeed leads to a longer progression free and overall survival.
The main research question is: does the use of the PlasmaJet Surgical Device in surgery for advanced stage ovarian
cancer result in an increased number of complete cytoreductive surgeries when compared with conventional
surgical techniques. Secondary study objectives are: 30-day morbidity, duration of surgery, blood loss, length of
hospitalisation, Quality of Life, disease-free survival, overall survival, percentage colostomy, cost-effectiveness.
Methods: The study design is a multicentre single-blinded superiority RCT in two university and nine non-university
hospitals in The Netherlands. Three hundred and thirty women undergoing cytoreductive surgery for advanced
stage ovarian carcinoma (FIGO Stage IIIB-IV) will be randomized into two arms: use of the PlasmaJet (intervention
group) versus the use of standard surgical instruments combined with electrocoagulation (control group). The
primary outcome is the rate of complete cytoreductive surgery in both groups.
Secondary study objectives are: 30-day morbidity, duration of surgery, blood loss, length of hospitalisation, Quality of
Life, disease-free survival, overall survival, percentage colostomy, cost-effectiveness. Quality of life will be evaluated
using validated questionnaires at baseline, at 1 and 6months after surgery and at 1, 2, 3 and 4 years after surgery.
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Discussion: We hypothesize the additional value of the use of the PlasmaJet in CCS for advanced stage epithelial
ovarian cancer. More knowledge about efficacy, side effects, recurrence rates, cost effectiveness and pathology findings
after using the PlasmaJet Device is advocated. This RCT may aid in this void.
Trial registration: Dutch Trial Register NTR6624. Registered 18 August 2017.
Medical Ethical Committee approval number: NL62035.078.17 (Medical Ethical Committee Erasmus Medical Centre
Rotterdam).
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Background
Ovarian cancer is the seventh most common cancer in
women worldwide with 239.000 new cases diagnosed in
2012. In The Netherlands 1325 patients were affected by
ovarian cancer in 2016; of these 80% were diagnosed
with advanced stage disease, for which surgical cytore-
duction combined with chemotherapy is indicated [1–3].
During the last decade, surgical and chemotherapeutic
treatment has not led to significant improvement in sur-
vival. In surgical treatment it is important that all visible
tumour is removed (complete cytoreductive surgery,
CCS) because the progression-free survival (PFS) and
overall survival (OS) after complete cytoreduction is sig-
nificantly longer than after optimal cytoreductive sur-
gery, where tumour volume of up to 1cm2 remains in
the abdomen [4–10]. In some cases it is impossible to
achieve complete cytoreduction with conventional sur-
gery due to the presence of many small tumour foci
scattered on the intestines. Electrosurgery is unsuitable
for tissues such as the intestine because of lateral ther-
mal spread and depth of tissue destruction [11].
The PlasmaJet Surgery Device is an advanced energy
system delivering pure plasma to the tissues. Plasma is a
highly energized phase of gas which is short-lived and
quickly dissipates at the targeted site of application,
allowing controlled use [12, 13].
PlasmaJet is able to vaporize small tumour spots on
intestine, mesentery, peritoneal surface, liver and spleen
and is able to dissect peritoneum from the underlying
tissue without muscle impulses and with less tissue dam-
age than with conventional electrosurgery [11]. In the
case series published on this subject application of the
PlasmaJet during cytoreduction resulted in higher rates
of CCS (79%) and fewer colostomies without any add-
itional complications [14–20].
In this study, we will compare the success rate of
CCS with the use of conventional surgery including
electrocoagulation (control) with the addition of Plas-
maJet Device (intervention) in a single blinded multi-
centre randomized controlled trial (RCT) to evaluate
the effectiveness of the PlasmaJet when applied in the
surgical treatment of women with advanced-stage ovar-
ian cancer [21].
Methods/design
Setting and study population
This study is called the PlaComOv-study. It is an acronym
for ‘Will the use of the PLAsmajet device improve the rate
of COMplete cytoreductive surgery for advanced stage
OVarian cancer.
In this study, 330 patients with a FIGO IIIB-IV epithelial
ovarian cancer, carcinoma of the fallopian tube or extra-
ovarian epithelial ovarian cancer(peritoneal cancer) in
whom the surgical goal is to achieve complete cytoreduc-
tion will be included. Patients should to be fit for CCS and
chemotherapy.
Patients from the following Dutch hospitals may be in-
cluded: Albert Schweitzer (Dordrecht), Bravis (Bergen op
Zoom), Catharina Cancer Institute (Eindhoven), Erasmus
MC (Rotterdam), Franciscus Gasthuis and Vlietland
(Rotterdam), Groene Hart Hospital (Gouda), Haags Med-
isch Centrum (Den Haag), Haga Hospital (Den Haag),
Leids University MC (Leiden), Medisch Spectrum Twente
(Enschede), Reinier de Graaf Groep (Delft).
All surgeons are trained and certified in the use of
PlasmaJet during the preparation of the study.
This study will compare the complete cytoreductive
surgery rate when using electrocoagulation only (stand-
ard) with that achieved with additional use of the Plas-
maJet Surgical Device (intervention). We expect that use
of the PlasmaJet during surgery will result in a higher
rate of complete cytoreduction and fewer colostomies
[14–20].
Standard therapy is primary cytoreductive (upfront)
surgery followed by chemotherapy, or neoadjuvant
chemotherapy followed by interval cytoreductive sur-
gery. Standard chemotherapy comprises of 6 cycles of
carboplatin and paclitaxel, with a duration of 21 days
for each cycle [1]. In upfront cytoreductive surgery, all
6 cycles of chemotherapy are given after surgery. In
interval cytoreductive surgery, 3 cycles of chemotherapy
are administered prior to surgery and 3 cycles there-
after. Patients from both the upfront and interval cytor-
eductive groups may be included.
The standard of care is to reach complete cytoreduc-
tion in all women who are fit to undergo extensive sur-
gery. This radical surgery may involve bowel surgery
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sometimes including colostomy. Electrocoagulation (Dia-
thermy, LigaSure), scalpel and scissors are used during con-
ventional surgery to remove visible tumour and to dissect
tumour tissue from peritoneal surfaces. The disadvantage
of electrocoagulation is the lateral thermal spread and the
depth of tissue destruction, which render it unsuitable for
use on the intestines. Electrocoagulation (Diathermy, Liga-
Sure), scalpel, scissors and PlasmaJet are used when indi-
cated during surgery in the intervention arm.
Inclusion criteria
In order to be eligible to participate in this study, a sub-
ject must meet all of the following criteria:
– patients with epithelial ovarian, tuba or peritoneal
carcinoma FIGO IIIB-IV who are fit enough to
undergo radical cytoreductive surgery as discussed
in the Tumorboard. Patients can either be scheduled
for primary cytoreduction or for interval cytoreduc-
tion after neoadjuvant chemotherapy
– patients should understand the patient information
form and sign informed consent
– pre-operative CT scan meets criteria for resectability
Exclusion criteria
A potential subject who meets any of the following cri-
teria will be excluded from participation in this study:
– patients who are not willing to participate or not
able to give their informed consent (language
barrier) and patients who are not willing to undergo
extensive surgery
– patients who are unfit to undergo extensive surgery
(assessed by gynaecologist and anaesthesiologist and
discussed in Tumorboard)
– patients who are not fit enough to get the standard
complete chemotherapy (six cycles carboplatin
paclitaxel) (assessed by medical oncologist and
discussed in Tumorboard)
– patients with a non-epithelial, borderline ovarian
tumour or an ovarian metastasis of another primary
tumour
– patients with recurrence of ovarian cancer.
Primary outcome
The primary study objective is to determine the rate of
complete cytoreductive surgery in each group.
Secondary outcomes
 Complication rate (30 day-morbidity)
 Duration of surgery and hospital stay
 Blood loss during surgery and number of blood
transfusions
 Number of partial bowel resections and colostomies
 Progression free survival [22]
 Overall survival [22]
 Quality of life (questionnaires filled in prior to
surgery, at 1 and 6 months and at 1, 2, 3 and 4 years
after surgery
 Accuracy of presurgical structured reporting of CT
scans (according to a structured checklist). This will
be compared with surgical findings (as recorded by a
Gynaecological Oncologist immediately after
surgery) and histological findings [23–28].
 Histology: depth of tissue destruction [29–32]
 Cost effectiveness analysis [33–37]: Costs per
(complete) cytoreduction and costs per gained life
year QALY
 Total number of chemotherapy courses during
overall survival
 Comparison of completeness of surgery between
both study groups according to an independent
review of the operation field by photos
A histology review will be carried out in a subpopula-
tion of 30 patients from the PlasmaJet group (15 primary
cytoreductive surgery, 15 interval cytoreductive surgery).
We will study at specific spots of macroscopic tumour
during surgery. One spot will be vaporized with Plasma-
Jet Device and analysed at the presence of residual
tumour. Another spot will be the control sample.
Our hypothesis is that vaporization by the PlasmaJet
Device will result in less tissue damage than electro-
coagulation and that we shall not find vital tumour cells
in tissue treated with PlasmaJet.
Intervention group
In the intervention group, the PlasmaJet Device will be
used if necessary as an additional device during cytore-
ductive surgery.
PlasmaJet Surgical Device uses neutral argon plasma to
vaporize small tumour nodules with minimal collateral
damage [11–14]. This device helps to achieve complete
cytoreductive surgery in patients with advanced stage
ovarian cancer, most particularly by ablating small tumour
foci on the abdominal peritoneum, diaphragm, intestinal
mesentery and bowel serosa.
Control group
In the control group, standard surgical instruments com-
bined with electrocoagulation will be used during cytore-
ductive surgery.
Assignment of intervention
The study will be explained verbally to the patient by the
gynaecologist, and patients will receive written informa-
tion in accordance with Good Clinical Practice guidelines.
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Those wishing to participate will sign an informed consent
form and will be randomized preoperatively. It is not al-
ways possible to assess the presence and stage of ovarian
cancer preoperative, and in some cases it is unknown
whether enlarged ovaries are malignant. In these cases,
women can be randomized preoperatively and the gynae-
cologist will decide during the surgery whether the patient
is eligible to be included in the study, depending on the
result of frozen section and tumour stage.
Computer randomization will be used to allocate pa-
tients to the intervention or control group. Randomization
will be carried out in blocks of varying size prior to sur-
gery. Inclusions will be stratified depending on high or
low suspicion of peritoneal carcinomatosis (based on
the pre-operative CT-scan), primary and interval cytore-
ductive surgery, and the use of OVHIPEC during surgery
or not [38–40].
The RCT is single blinded: the patient does not know
to which arm she has been assigned.
Data collection
Coded data are stored both on paper and in an elec-
tronic database. Collected data are stored in a digital
case report form (CRF). Raw data is available only to the
principal and coordinating investigator.
Patient characteristics will be stored in ‘Open Clinica’
and analysed in SPSS.
A CRF will be completed preoperatively, postoperatively-
discharge and at 1½, 6, 12, 24 and 48months postopera-
tively (Fig. 1).
Prior to surgery and at 1½, 6, 12, 24, 36 and 48 months
postoperatively, a quality of life questionnaire will be
completed (EORTC, QLQ-30 and EQ-5D) (Fig. 1).
The following data are recorded:
Preoperatively:
Patient characteristics, presence of germline mutations
such as BRCA1 or 2, investigations carried out to make
the diagnosis, outcome of structural reported CT-scan,
chemotherapy, quality of life.
(Post)operatively:
Adverse effects of chemotherapy, operative parameters,
tumour location, effectiveness of PlasmaJet during
surgery, outcome of surgery, postoperative
hospitalization, hospital discharge.
4–6 weeks follow-up:
Complications postoperatively, re-hospitalization,
histology outcome, planned chemotherapy, quality
of life.
6 months follow-up:
Fig. 1 Flowchart of the study design
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Complications of chemotherapy, re-hospitalization, in-
dication of recurrence of malignancy, quality of life.
1,2,3 and 4 years follow-up:
Indication of recurrence of malignancy, new lines of
chemotherapy administered, quality of life.
Statistical considerations
Sample size calculations are based on our primary out-
come measure. To demonstrate the additional value of the
PlasmaJet, we assume an absolute increase of 15% in
complete cytoreductive surgery in the PlasmaJet group
(77% versus 62%). With a total type I error (alpha) of 5%,
and a Type II error (beta) of 20%, 147 patients should be
enrolled in each research arm.
Assuming a 12% loss of follow-up, a total of 330 pa-
tients should be recruited.
Statistical analysis
The primary outcome measure, percentage complete
surgery, will be calculated for each arm of the study to-
gether with a confidence interval based on the Wilson
method. They will be compared using a chi-squared test
with continuity correction. We will also calculate the
risk difference. This will be presented with a 95% confi-
dence interval (calculated using Newcombe’s method).
The study will be analysed according to the intention
to treat principle. An exploratory subgroup analysis will
be performed in a subset of patients with more than 50
lesions in the abdomen (peritoneal carcinomatosis), as
complete cytoreductive surgery is not feasible for this
group of patients. No multiplicity correction will be per-
formed for these subgroup analyses.
Continuous secondary outcomes (duration of surgery,
duration of hospital stay, blood loss) will be calculated
using t-tests and the discrete variables (complication
rate, bowel surgery, colostomies, number of chemother-
apy courses) using chi-square tests using continuity
correction.
All outcomes will be analysed using regression tech-
niques. Progression-free and overall survival will be stud-
ied using the Kaplan-Meier method. Additionally Cox
regression will be performed to study the influence of
peritoneal carcinomatosis, complete, optimal or subopti-
mal cytoreduction. A p-value < 0.05 will be considered
significant.
Multiple imputation using chained equations will be
used for missing co-values.
The other study parameters will be analysed as follows:
1. Progression free survival (after 5 and 10 years)
(Kaplan-Meier method)
2. Overall survival (after 5 and 10 years) (Kaplan-Meier
method)
3. Cost per life year gained
4. Number of chemotherapy courses (chi-square tests
using continuity correction)
No interim analysis for futility and effectiveness will be
performed. A safety committee has been installed to
monitor harm. The committee will receive data on safety
and harm after each group of 50 consecutive patients
and may advise stopping the trial for safety reasons after
each analysis.
Ethics and dissemination
The study has been approved by the Medical Ethical
Committee of Erasmus Medical Centre Rotterdam. The
study will be performed according to the standards out-
lined in the Declaration of Helsinki. Ethics committee
approval has been granted.
Patients will receive verbal and written information
from their gynaecologist during the intake for surgery.
Randomization happens after signing of the Informed
Consent.
Subjects can leave the study at any time for any reason
if they wish to do so without any consequences. The in-
vestigator can decide to withdraw a subject from the
study for urgent medical reasons. At this moment there
are no specific criteria for withdrawal. After withdrawal
the patient will be replaced since this is an intention to
treat trial.
A monitoring plan is installed to ensure patients’
safety and the quality of this trial. Adverse events are
recorded and reported by the sponsor through a local
protocol. Study results will be offered for publication
in international medical journals and on the website
of the patient association for women with gynaeco-
logical cancer.
Discussion
This study will contribute to the understanding of surgi-
cal treatment in patients with high stage ovarian cancer
and will answer questions on implementation of the
PlasmaJet Surgical Device. The results of this study will
demonstrate whether the use of PlasmaJet Surgical De-
vice will lead to a greater chance of complete cytoreduc-
tive surgery, and whether there is prolonged progression
free and overall survival after operations conducted with
this device.
The trial aims to study the efficacy of the Plasma-
Jet, side effects, survival rates and cost effectiveness,
in comparison with conventional surgery. Pathology
findings such as the presence of microscopic vital
tumour after vaporisation with PlasmaJet and the
depth of tissue damage after using the device will be
studied.
A strength of this single blinded RCT is the use of
questionnaires of Quality of Life (EORTC QLQ-30 and
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EQ-5D) and the involvement of the patient association of
women with gynaecological cancer in The Netherlands.
Trial status
Approved by Medical Ethical Committee Medical Ethical
Committee Erasmus Medical Centre Rotterdam, The
Netherlands on 20-11-2017. Recruitment started on
30-1-2018. Protocol version 3.0.
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